How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,087 results for

Peptic Ulcer Disease

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Subtotal Gastrectomy With Billroth II Anastomosis Is Associated With a Low Risk of Ischemic Stroke in Peptic Ulcer Disease Patients: A Nationwide Population-Based Study. (PubMed)

Subtotal Gastrectomy With Billroth II Anastomosis Is Associated With a Low Risk of Ischemic Stroke in Peptic Ulcer Disease Patients: A Nationwide Population-Based Study. Duodenal diversion can ameliorate lipid and glucose metabolism. We assessed the risk of stroke after subtotal gastrectomy with Billroth II anastomosis (SGBIIA) in peptic ulcer disease (PUD). We identified 6425 patients who received SGBIIA for PUD between 1998 and 2010 from the Taiwan National Health Insurance Research Database (...) as the study cohort; we frequency-matched them with 25,602 randomly selected controls from the PUD population who did not receive SGBIIA according to age, sex, index year, and comorbidities including hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease (COPD), and obesity. All patients were followed until the end of 2011 to determine the incidence of stroke. The incidence of stroke was lower

Full Text available with Trip Pro

2016 Medicine

62. Peptic ulcer disease in living liver donors: A longitudinal population-based study. (PubMed)

Peptic ulcer disease in living liver donors: A longitudinal population-based study. The objective of this nationwide cohort study was to investigate the risk of peptic ulcer disease (PUD) in living liver donors (LDs). A total of 1333 LDs and 5332 matched nondonors were identified during 2003-2011. Hospitalized patients identified as LDs were assigned to the LD cohort, and the non-LD comparison cohort comprised age- and sex-matched nondonors. Cumulative incidences and hazard ratios (HRs) were

2016 American Journal of Transplantation

63. The comparison of monopolar hemostatic forceps with soft coagulation versus hemoclip for peptic ulcer bleeding: a randomized trial (with video). (PubMed)

The comparison of monopolar hemostatic forceps with soft coagulation versus hemoclip for peptic ulcer bleeding: a randomized trial (with video). Although various methods are used in the treatment of peptic ulcer bleeding, there is not a standard recommended approach. The choice depends on multiple factors such as location of the ulcer, clinical experience of the endoscopist, and local facilities of the clinic. We aimed to compare the efficacy of monopolar hemostatic forceps soft coagulation (...) (MHFSC) and hemoclips (HCs) in the treatment of peptic ulcer-related upper GI bleeding.The study group included patients who had GI bleeding due to Forrest 1a, 1b, and 2a gastric or duodenal ulcers within 1 year. Patients with bleeding diathesis, history of gastrectomy, pregnancy, or younger than age 18 years were excluded. The remaining were randomized to MHFSC and HC treatment groups and compared in terms of clinical and endoscopic features, initial hemostasis success rates, recurrent bleeding

2018 Gastrointestinal endoscopy

64. Evaluation of risk factors for perforated peptic ulcer. (PubMed)

with PPU, and 272 were a control group. Univariate analysis showed statistical significance in many categories. Four different models of multivariate analyses were conducted, and significant differences were found for muscular defense and a history of peptic ulcer disease (PUD) in all models. The conditional forced-entry analysis of muscular defense showed an odds ratio (OR) of 23.8 (95% confidence interval [CI]: 5.70-100.0), and the analysis of PUD history showed an OR of 6.40 (95% CI: 1.13-36.2 (...) Evaluation of risk factors for perforated peptic ulcer. The aim of this study was to evaluate the prediction factors for perforated peptic ulcer (PPU).At St. Luke's International Hospital in Tokyo, Japan, a case control study was performed between August 2004 and March 2016. All patients diagnosed with PPU were included. As control subjects, patients with age, sex and date of CT scan corresponding to those of the PPU subjects were included in the study at a proportion of 2 controls for every

Full Text available with Trip Pro

2018 BMC Gastroenterology

65. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. (PubMed)

the contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients taking these drugs.Among patients with peptic ulcer disease diagnosed by endoscopy from 01/2004 to 12/2014 (N = 1719, 60% males, age 65.8 ± 14.5), 56.9% had peptic ulcer bleeding (cases) and 43.1% uncomplicated peptic ulcer disease (controls). Demographics, intake of nonsteroidal anti-inflammatory drugs, aspirin, non-aspirin antiplatelet agents, anticoagulants, selective serotonin reuptake inhibitors, proton pump (...) and aspirin users.Helicobacter pylori infection increases the risk of peptic ulcer bleeding in peptic ulcer disease patients on nonsteroidal anti-inflammatory drugs, aspirin and non-aspirin antiplatelet agents. H. pylori-positive patients on combined antiplatelet therapy carry the highest risk for peptic ulcer bleeding.© 2018 John Wiley & Sons Ltd.

2018 Alimentary Pharmacology & Therapeutics

66. Once Versus Twice-Daily Oral Proton Pump Inhibitor Therapy for Prevention of Peptic Ulcer Rebleeding: A Propensity Score-Matched Analysis (PubMed)

Once Versus Twice-Daily Oral Proton Pump Inhibitor Therapy for Prevention of Peptic Ulcer Rebleeding: A Propensity Score-Matched Analysis After inpatient management of upper gastrointestinal bleeding (GIB) due to peptic ulcer disease (PUD), oral proton pump inhibitor (PPI) therapy is recommended at discharge to decrease rebleeding risk and improve ulcer healing. Our aim is to determine whether once-daily oral PPI dosing at hospital discharge is associated with inferior 30-day rebleeding

Full Text available with Trip Pro

2018 Gastroenterology research

67. Study to Evaluate Efficacy and Safety of Wound Dressing Solution Containing EGF in Patients With Peptic Ulcers Bleeding

First Posted : March 19, 2018 Last Update Posted : March 19, 2018 Sponsor: CGBio Inc. Information provided by (Responsible Party): CGBio Inc. Study Details Study Description Go to Brief Summary: This is a prospective, single-blinded, randomized study to evaluate the efficacy and safety of CEGP003 in patients with acute peptic ulcers bleeding, compared to endoscopic epinephrine injection therapy. Condition or disease Intervention/treatment Phase Peptic Ulcer Bleeding Device: CEGP003 Device: Injection (...) MeSH terms: Layout table for MeSH terms Ulcer Hemorrhage Peptic Ulcer Peptic Ulcer Hemorrhage Pathologic Processes Duodenal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Stomach Diseases Gastrointestinal Hemorrhage Epinephrine Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Adrenergic beta-Agonists Bronchodilator Agents Autonomic Agents Peripheral

2018 Clinical Trials

68. Choledochoduodenal fistula due to peptic duodenal ulcer diagnosed by X-barium meal study: interest of medical treatment (PubMed)

Choledochoduodenal fistula due to peptic duodenal ulcer diagnosed by X-barium meal study: interest of medical treatment Peptic ulcer complication has decreased over le last years. Spontaneous bilio-digestive fistulas, in the absence of primary biliary disease, remain a very unusual complication of the upper digestive tract. The choledochoduodenal fistula is an extremely rare entity which can be caused by a duodenal peptic ulcer. It appears with the symptoms of peptic ulcer disease (...) . They are diagnosed incidentally on radiological exams. It was suspected after finding pneumobilia on abdominal ultrasound and confirmed by X-barium meals study. The purpose of this observation is to report the case of a patient presenting a choledochoduodenal fistula diagnosed by X-barium meal to underline the importance of this radiological exam to diagnose this disease and to insist on the conservative treatment for choledochoduodenal fistula caused by a duodenal peptic ulcer. The prognosis of patients treated

Full Text available with Trip Pro

2018 The Pan African medical journal

69. Atypical anastomotic malignancies of small bowel after subtotal gastrectomy with Billorth II gastroenterostomy for peptic ulcer: Report of three cases and review of the literature (PubMed)

that originated in the efferent loop after Billroth II gastrectomy because of duodenal ulcer but none reporting Braun anastomosis adenocarcinoma following partial gastrectomy for benign disease. We also did not find any case of efferent loop lymphoma following gastrectomy.Anastomotic gastric cancer following distal gastrectomy for peptic ulcer is a well-established clinical entity. However, malignancies of the afferent or efferent loop of the gastrointestinal anastomosis are extremely uncommon (...) Atypical anastomotic malignancies of small bowel after subtotal gastrectomy with Billorth II gastroenterostomy for peptic ulcer: Report of three cases and review of the literature To present patients who developed small-bowel malignancy at the level of the gastrointestinal anastomosis decades after a subtotal gastrectomy for ulcer, to review relevant literature, and to attempt to interpret the reasons those cancers developed to these postsurgical non-gastric sights.For the current retrospective

Full Text available with Trip Pro

2018 World journal of gastrointestinal oncology

70. Association of IL-1B+3954 and IL-1RN Polymorphisms in Chronic Gastritis and Peptic Ulcer (PubMed)

ulcer [Odds Ratio (OR)]=2.63, 95% Confidence Interval (CI)= (1.47-4.70) (OR=3.40, CI=1.72-6.71) respectively and the IL-1B+3954 T allele was associated with chronic gastritis (OR=1.64, 95% CI=1.13-2.36). Moreover, patient carrying IL-1RN L/2 and allele 2 showed an increased risk of peptic ulcer (OR=2.97, CI=1.72-5.11, OR=1.64, CI=1.13-2.36), respectively.IL-1B and IL-1RNare associated with an increased risk for chronic gastritis and peptic ulcer disease. (...) Association of IL-1B+3954 and IL-1RN Polymorphisms in Chronic Gastritis and Peptic Ulcer Helicobacter pylori are the main cause of chronic inflammation and peptic ulcer. We aimed to determine if IL-1B+3954 and IL-1RN polymorphisms are associated with the risk of chronic gastritis and peptic ulcer in Iranian population.In this case-control study, from 198 individuals enrolled by Mohammadi Hospital, Bandar Abbas, southern Iran from 2012 to 2014 and who showed the symptoms of chronic gastritis

Full Text available with Trip Pro

2018 Iranian journal of public health

71. A comparative study of subsequent liver cirrhosis risk in non- helicobacter pylori infected peptic ulcer patients with and without vagotomy: an Asian population cohort study. (PubMed)

A comparative study of subsequent liver cirrhosis risk in non- helicobacter pylori infected peptic ulcer patients with and without vagotomy: an Asian population cohort study. Hepatic parasympathetic nerves branch off the vagus nerve. The vagal and hepatic nervous systems are important in liver physiological processes and some diseases such as diabetes, obesity, and liver cirrhosis. We were interested in vagal nerve integrity and subsequent diseases in peptic ulcer patients. Herein, we used (...) National Health Insurance database in Taiwan and retrospectively assessed the risk of developing liver cirrhosis in peptic ulcer patients with and without complications by surgical treatments.A cohort of 357 423 peptic ulcer patients without Helicobacter pylori, hepatitis B/C virus infection, and alcoholism from 2001 to 2008 was established. A randomly selected cohort of 357 423 people without peptic ulcer that matched by age, gender, comorbidities, and index year was used for comparison. The risks

2018 Journal of gastroenterology and hepatology

72. Platelet Rich Plasma in Bleeding Peptic Ulcer

provided by Amr Shaaban Hanafy, Zagazig University: platelet rich plasma Additional relevant MeSH terms: Layout table for MeSH terms Ulcer Hemorrhage Peptic Ulcer Peptic Ulcer Hemorrhage Pathologic Processes Duodenal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Stomach Diseases Gastrointestinal Hemorrhage Epinephrine Racepinephrine Epinephryl borate Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms (...) Platelet Rich Plasma in Bleeding Peptic Ulcer Platelet Rich Plasma in Bleeding Peptic Ulcer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Platelet Rich Plasma in Bleeding Peptic Ulcer (PRP) The safety

2018 Clinical Trials

73. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials (PubMed)

Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials Gastroprotectant drugs are used for the prevention and treatment of peptic ulcer disease and might reduce its associated complications, but reliable estimates of the effects of gastroprotectants in different clinical settings are scarce. We aimed to examine the effects of proton-pump inhibitors (PPIs), prostaglandin analogues, and histamine-2 (...) , 95% CI 0·60-0·78; p<0·0001), blood transfusion (0·75, 0·65-0·88; p=0·0003), further endoscopic intervention (0·56, 0·45-0·70; p<0·0001), and surgery (0·72, 0·61-0·84; p<0·0001), but did not significantly reduce mortality (OR 0·90, 0·72-1·11; p=0·31). PPIs had larger protective effects than did H2RAs for further bleeding (phet=0·0107) and blood transfusion (phet=0·0130).Gastroprotectants, in particular PPIs, reduce the risk of peptic ulcer disease and its complications and promote healing

Full Text available with Trip Pro

2018 The lancet. Gastroenterology & hepatology

74. Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients

. They were randomly assigned into two groups, ilaprazole and omeprazole, to be treated for up to 30 days. The primary endpoint was the hemostasis rate at the end of 72 hours. Secondary end points include ulcer staging changes within 72 hours, effective rate of hemostasis, hemostasis duration, average blood transfusion and rebleeding rate, etc. Condition or disease Intervention/treatment Phase Peptic Ulcer Hemorrhage Drug: Ilaprazole Drug: Omeprazole Drug: Ilaprazole tablet Drug: amoxicillin (...) , 2017 Last Update Posted: December 6, 2017 Last Verified: November 2017 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Livzon Pharmaceutical Group Inc.: Peptic ulcer hemorrhage Proton Pump Inhibitor Additional relevant MeSH terms: Layout table for MeSH terms Ulcer Hemorrhage Peptic Ulcer Peptic Ulcer Hemorrhage Pathologic Processes Duodenal Diseases Intestinal Diseases Gastrointestinal

2017 Clinical Trials

75. IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients

and omeprazole, to be treated for up to 30 days and be seen at day 3, 4, 7, 14 and 30. The primary endpoint was the hemostasis rate (hemostatic groups with endoscopy check ) and re-bleeding rate ( bleeding groups with endoscopy check) within 72 hours. Secondary end points include effective rate of hemostasis, mean volume of blood transfusion, the length of stay and re-bleeding rate, etc. Condition or disease Intervention/treatment Phase Peptic Ulcer Hemorrhage Drug: Ilaprazole Drug: omeprazole Phase 2 (...) Numbers: Livzon-IYI-Ⅱ First Posted: December 5, 2017 Last Update Posted: December 6, 2017 Last Verified: November 2017 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Ulcer Hemorrhage Peptic Ulcer Peptic Ulcer Hemorrhage Pathologic Processes Duodenal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Stomach Diseases

2017 Clinical Trials

76. Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies. (PubMed)

Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies. The presence of cirrhosis increases the mortality of patients with peptic ulcer bleeding (PUB). Both acute variceal bleeding (AVB) and PUB are associated with substantial mortality in cirrhosis. This multicenter cohort study was performed to assess whether the mortality of patients with cirrhosis with PUB is different from that of those with AVB. Patients (...) of death. Only 2% of the PUB group versus 3% of the AVB group died with uncontrolled bleeding (P = 0.39), whereas the majority of patients in either group died from liver failure or attributed to other comorbidities.Using current first-line therapy, patients with cirrhosis and acute peptic ulcer bleeding have a similar survival than those with variceal bleeding. The risk of further bleeding is higher in patients with variceal hemorrhage. However, few patients in both groups died from uncontrolled

2017 Hepatology

77. Association of CagA EPIYA-D or EPIYA-C phosphorylation sites with peptic ulcer and gastric cancer risks: A meta-analysis. (PubMed)

Association of CagA EPIYA-D or EPIYA-C phosphorylation sites with peptic ulcer and gastric cancer risks: A meta-analysis. Increasingly, studies have focused on the relationship between Helicobacter pylori (H pylori) cytotoxin associated gene A protein (CagA) Glu-Pro-Ile-Tyr-Ala (EPIYA)-D motifs or multiple EPIYA-C phosphorylation sites and peptic ulcer disease (PUD) or gastric cancer (GC) risk. However, the conclusions have been inconsistent. The aim of this meta-analysis was to evaluate (...) risk (OR=1.91, 95% CI=1.19-3.07, P = .008). However, 1 EPIYA-D motif was not significantly associated with PUD (OR = 0.90, 95% CI = 0.46-1.76, P = .764), gastric ulcer (GU) (OR = 0.85, 95% CI = 0.27-2.63, P = .771), or duodenal ulcer (DU) (OR = 0.89, 95% CI = 0.25-3.16, P = .859) risk. Compared with no more than 1 EPIYA-C motif, multiple motifs were associated with increased PUD (OR = 2.33, 95% CI = 1.29-4.20, P = .005) and DU (OR = 2.32, 95% CI = 1.08-5.00, P = .031) risk in Asia and GC risk

Full Text available with Trip Pro

2017 Medicine

78. Over-the-scope Clip Versus Through-the-scope Clip for Endoscopic Hemostasis of High Risk Bleeding Peptic Ulcers

. ClinicalTrials.gov Identifier: NCT03551262 Recruitment Status : Recruiting First Posted : June 11, 2018 Last Update Posted : January 23, 2019 See Sponsor: Azienda USL Modena Information provided by (Responsible Party): Dr. Mauro Manno, Azienda USL Modena Study Details Study Description Go to Brief Summary: To compare in a multicenter, prospective, randomized, controlled trial the efficacy and safety of OTSC versus TTS clip for first-line hemostasis of high risk bleeding peptic ulcers Condition or disease (...) : No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: No Additional relevant MeSH terms: Layout table for MeSH terms Ulcer Hemorrhage Peptic Ulcer Peptic Ulcer Hemorrhage Pathologic Processes Duodenal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Stomach Diseases Gastrointestinal Hemorrhage Hemostatics Coagulants

2017 Clinical Trials

79. The Use of Over-the-scope-clip for Prevention of Rebleeding in High Risk Peptic Ulcers

The Use of Over-the-scope-clip for Prevention of Rebleeding in High Risk Peptic Ulcers The Use of Over-the-scope-clip for Prevention of Rebleeding in High Risk Peptic Ulcers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. The Use of Over-the-scope-clip for Prevention of Rebleeding in High Risk Peptic Ulcers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03160911 Recruitment Status : Recruiting First Posted : May 19

2017 Clinical Trials

80. Helicobacter pylori from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool (PubMed)

Helicobacter pylori from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool Around 70-90% of peptic ulcer disease (PUD) is due to Helicobacter pylori and requires treatment with antimicrobials to which these bacteria are susceptible. Common H. pylori diagnostic tests do not provide drug susceptibility data. Using the GenoType HelicoDR PCR test designed for gastric biopsies for simultaneous

Full Text available with Trip Pro

2017 BioMed research international

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>